PI 166

Drug Profile

PI 166

Alternative Names: PI-166

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator University of New South Wales
  • Developer Progen Pharmaceuticals Limited; TBG Diagnostics Limited
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Liver cancer

Most Recent Events

  • 22 Jul 2008 Discontinued - Phase-I for Liver cancer in Australia (IV)
  • 25 Jun 2007 Progen Pharmaceuticals raises $A34.1 million in Entitlements Offer
  • 15 May 2007 Progen Pharmaceuticals receives $A4.6 million grant through the Australian Government's Pharmaceuticals Partnerships Program
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top